Trial · NCT05179499
Early Vasopressors in Sepsis
NCT05179499, Phase 3, Recruiting, NHS Greater Glasgow and Clyde
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Early Vasopressors in Sepsis. Trials, record NCT05179499. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05179499
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Early Vasopressors in Sepsis
- NCT number
- NCT05179499
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 1,006 participants, estimated
- Lead sponsor
- NHS Greater Glasgow and Clyde
- Conditions
- Sepsis
- Interventions
- Norepinephrine, Balanced Crystalloid
- First posted
- 2022-01-05
- Last updated
- 2026-02-12
- Other registries' IDs
- eudract:2021-006886-39
Source ClinicalTrials.gov
Registered outcomes24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The primary objective is to determine whether early PVI (within 12 hours of admission) targeted to MAP of ≥65 mmHg improves clinical effectiveness in hospitalised adult patients with septic shock compared with usual care, in the first 48 hours. | 90 days post randomisation | The primary objective is measured by the Primary outcome of 'Days Alive and Out of Hospital at 90 Days'. |
| Secondary | Accumulated Total Volume of IV fluid | 6,12, 24, 48 and 72 hours post randomisation | Accumulated volume of IV fluid delivered in each arm - excluding fluid volumes less than 100ml |
| Secondary | Lactate clearance from baseline | 6, 12, 24, 48 & 72 hours post randomisation | Blood lactate value - arterial or venous |
| Secondary | Total Dose of Norepinephrine | 6, 12, 24, 48 and 72 hours post randomisation | Total dose of norepinephrine delivered by any route (peripheral or central) at each timepoint |
| Secondary | Proportion of patients who receive vasopressors | 6, 12, 24 and 48 hours after recruitment to the control arm | Proportion of patients recruited to control arm who receive any vasopressor (norepinephrine, vasopressin, metarminol, epinephrine) at each time point |
| Secondary | Proportion of patients who require central venous access | 24 and 48 hours post randomisation | Decision to treat based on treating clinician judgement |
| Secondary | Proportion of patients developing acute kidney injury | During the first 72 hours post randomisation | Acute kidney injury in line with the (p) RIFLE (paediatric Risk, Injury, Failure, Loss, End stage renal disease, AKIN (Acute kidney injury network) or KDIGO (Kidney Disease: Improving Global Outcomes) definitions by using any of the following criteria * a rise in serum creatinine of 26 micromol/litre or greater within 48 hours * a 50% or greater rise in serum creatinine known or presumed to have occurred within the past 7 days * a fall in urine output to less than 0.5 ml/kg/hour for more than 6 hours in adults |
| Secondary | Proportion of patients receiving parenteral corticosteroid | 24, 48 & 72 hours post randomisation | defined as new prescription of parenteral corticosteroid |
| Secondary | Length of hospital stay for index admission | up to hospital discharge | index hospital admission ends when the patient is discharged from the facility providing definitive treatment for the episode of sepsis leading to inclusion in the study |
| Secondary | Proportion of participants needing renal replacement therapy during index hospital admission | index admission | decision to treat based on treating clinician judgement; participants who receive new renal replacement therapy; participants with chronic renal replacement initiated prior to the index admission will not be eligible to meet this endpoint |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05179499
GET https://conductscience.org/api/trials/v1/NCT05179499/registered?page=2